SYNDAX PHARMACEUTICALS INC

Insider Botwood’s buying and selling at Syndax signals confidence in a new oncology trial and $250 M fundraise, showing leadership’s balanced growth strategy.

CEO Metzger’s big buy‑back at Syndax signals management confidence, boosting investor sentiment while highlighting the biotech’s pipeline potential.

Insider buying at Syndax Pharmaceuticals shows growing confidence in its oncology pipeline, potentially signaling undervaluation and future upside for investors.

Insider buying spurs confidence in Syndax Pharma, with Huber Martin’s large RSU grant suggesting a bullish outlook amid volatile shares.

Insider buying spree at Syndax Pharma shows leadership confidence despite volatility – learn how RSU moves may signal future upside.